Oncologia 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Oncologia 1, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
Crit Rev Oncol Hematol. 2022 Jan;169:103568. doi: 10.1016/j.critrevonc.2021.103568. Epub 2021 Dec 7.
Evidence for the choice of second line, standard vs high dose chemotherapy, (SDCT, HDCT) for patients with relapsed germ cell tumors (GCTs) comes mainly from retrospective studies.
relevant literature was reviewed, considering as endpoints both survival and long term quality of life (QoL). Patients with metastatic GCT progressing after first-line treatment at our Institution were retrospectively evaluated.
HDCT seems to achieve a higher rate of long-term remissions. QoL data for this group of patients are lacking. Our experience on 29 patients was in line with these results. Two-year OS for the 18 patients treated with one or two HDCT/PBSCT procedures was 47.5 %, while 2-year PFS was 44 %. For the 11 receiving SDCT 2-year OS was 36.4 %, and 2-year PFS was 32.7 %.
HDCT/PBSCT confirmed to be effective in treating patients with relapsed GCT, but prospective studies are needed.
对于复发生殖细胞瘤（GCT）患者，二线治疗选择标准剂量与高剂量化疗（SDCT、HDCT）的依据主要来自回顾性研究。
对相关文献进行了回顾，将生存和长期生活质量（QoL）作为主要终点进行考虑。回顾性评估了在本机构接受一线治疗后进展的转移性 GCT 患者。
HDCT 似乎能提高长期缓解率。但缺乏该组患者的 QoL 数据。我们对 29 例患者的经验与这些结果一致。18 例接受一次或两次 HDCT/PBSCT 治疗的患者 2 年 OS 为 47.5%，2 年 PFS 为 44%。11 例接受 SDCT 治疗的患者 2 年 OS 为 36.4%，2 年 PFS 为 32.7%。
HDCT/PBSCT 证实对治疗复发 GCT 有效，但仍需要前瞻性研究。
